scholarly journals Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50–80 years of age

2014 ◽  
Vol 10 (5) ◽  
pp. 1195-1203 ◽  
Author(s):  
Ted M Ross ◽  
Chyongchiou Jeng Lin ◽  
Mary Patricia Nowalk ◽  
Hsin-Hui Huang ◽  
Sarah M Spencer ◽  
...  
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Hemagglutination Inhibition ◽  
Trivalent Influenza Vaccine

scholarly journals Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons

2015 ◽  
Vol 11 (2) ◽  
pp. 386-390 ◽  
Author(s):  
Satoshi Hiroi ◽  
Saeko Morikawa ◽  
Keiko Nakata ◽  
Akiko Maeda ◽  
Tsuneji Kanno ◽  
...  
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Trivalent Influenza Vaccine

scholarly journals Immunoglobulin G, A and M response to influenza vaccination in different age groups: effects of priming and boosting

1986 ◽  
Vol 96 (3) ◽  
pp. 513-522 ◽  
Author(s):  
Walter E. P. Beyer ◽  
Jos T. M. Van Der Logt ◽  
Ruud van Beek ◽  
Nic Masurel
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Influenza Infection ◽  
Age Groups ◽  
Antibody Responses ◽  
Trivalent Influenza Vaccine ◽  
Antibody Capture ◽  
The Mean ◽  
Original Antigenic Sin

SUMMARYFifty volunteers, treated with an inactivated trivalent influenza vaccine containing A/Bangkok/1/79 (H3N2), A/Brazil/11/78 (H1N1) and B/Singapore/222/79 virus, were subdivided according to the estimated first exposure to influenza in their lifetime (priming) and the presence of antibodies against the vaccine components in the pre-vaccination sera. The isotypic antibody response (IgG, IgA, IgM) was determined by means of an antibody capture haemadsorption immunosorbent technique. For all three vaccine components, previously seropositive subjects produced antibodies of the IgG- and IgA-class more frequently than previously seronegative persons. Subjects primed to one of the influenza A subtypes showed more IgG and IgA responses in comparison with those unprimed (prime-effect). In contrast, IgM antibodies occurred in only 19 and 11% of primed, but in 59 and 54% of unprimed subjects, for A (H3N2) and A (HlNl), respectively. The incidence of IgM titre rises was not influenced by the prevaccination state. However, the mean magnitude of anti-A(H1N1)-IgM titre rises was greater in those previously seronegative. The concepts of primary and reinfection and of ‘original antigenic sin’ are discussed, and it is suggested that age and, if possible, serological state prior to antigen-exposure should be taken into account when studying isotypic antibody responses after influenza infection or vaccination.

scholarly journals A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 393
Author(s):  
Joanne Langley ◽  
Elodie Pastural ◽  
Scott Halperin ◽  
Shelly McNeil ◽  
May ElSherif ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Mosaic Virus ◽  
Hemagglutination Inhibition ◽  
Mononuclear Cells ◽  
Geometric Mean ◽  
Controlled Study ◽  
Cell Mediated Immunity ◽  
Adjuvant Effect ◽  
Trivalent Influenza Vaccine ◽  
Papaya Mosaic Virus

Inactivated influenza vaccines efficacy is variable and often poor. We conducted a phase 1 trial (NCT02188810), to assess the safety and immunogenicity of a novel nanoparticle Toll-like receptor 7/8 agonist adjuvant (Papaya Mosaic Virus) at different dose levels combined with trivalent influenza vaccine in healthy persons 18–50 years of age. Hemagglutination-inhibition assays, antibody to Influenza A virus nucleoprotein and peripheral blood mononuclear cells for measurement of interferon-gamma ELISPOT response to influenza antigens, Granzyme B and IFNγ:IL-10 ratio were measured. The most common adverse events were transient mild to severe injection site pain and no safety signals were observed. A dose-related adjuvant effect was observed. Geometric mean hemagglutination-inhibition titers increased at day 28 in most groups and waned over time, but fold-antibody responses were poor in all groups. Cell mediated immunity results were consistent with humoral responses. The Papaya Mosaic Virus adjuvant in doses of 30 to 240 µg combined with reduced influenza antigen content was safe with no signals up to 3 years after vaccination. A dose-related adjuvant effect was observed and immunogenicity results suggest that efficacy study should be conducted in influenza antigen-naïve participants.

Antibody response to the influenza vaccine in healthcare workers

Vaccine ◽  
2012 ◽  
Vol 30 (2) ◽  
pp. 436-441 ◽  
Author(s):  
Ema Sacadura-Leite ◽  
Antonio Sousa-Uva ◽  
Helena Rebelo-de-Andrade
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Healthcare Workers

scholarly journals A randomized controlled trial of antibody response to 2018–19 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children

Vaccine ◽  
2020 ◽  
Vol 38 (33) ◽  
pp. 5171-5177
Author(s):  
Krissy K. Moehling ◽  
Richard K. Zimmerman ◽  
Mary Patricia Nowalk ◽  
Chyongchiou Jeng Lin ◽  
Judith M. Martin ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Antibody Response ◽  
Influenza Vaccine ◽  
Controlled Trial ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document